Cirevetmab Antibody is a research-grade biosimilar monoclonal antibody targeting TGFB1/TGF-beta-1. It is a caninized IgG2, kappa antibody. Reactivity: Canine. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Transforming growth factor beta-1 proprotein (TGFB1) is a ~44 kDa protein. Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.